Acrux Limited · ASX:ACR
Acrux — Investor Presentation (September 2018)
18 slides from Acrux's investor presentation, Sep 18, 2018
Slide 1: ASX/Media Release: Acrux investor presentation
ASX/Media Release 18 September 2018 For personal use only Acrux investor presentation Melbourne, Australia; 18 September 2018: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to release a new investor presentation. Investment highlights • Diverse portfolio of 13 topical generic products
Slide 2: Acrux Investor Presentation
For personal use only ACRUX INVESTOR PRESENTATION (ASX: ACR) September 2018
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only High potential • 13 products in the generic topical portfolio, up from 7 in October 2017 topical generic • Addressable market of pipeline assets is >US$1.4bn portfolio Delivering on • Strong execution building the topical generic pipeline since 2015, submi
Slide 4: High Value Pipeline of Products – Implied Enterprise Value of <$11m
HIGH VALUE PIPELINE OF 13 PRODUCTS – IMPLIED ENTERPRISE VALUE OF <$11M For personal use only Implied enterprise value breakdown (A$m) With $28.5m cash as at 30 June, management reasonably expects there to be sufficient funding to progress the current pipeline through to launch 39.1 ➢ Typical costs f
Slide 5: Our Approach
OUR APPROACH For personal use only Market screening to identify high potential prescription 165 identified molecules, IDENTIFY topical products each with >US$10m in sales Acrux is developing a diversified portfolio of topically applied R&D team with highly specific topical expertise drive 13 molecul
Slide 6: Multiple Advantages for Generic Prescription Product Development
MULTIPLE ADVANTAGES FOR GENERIC PRESCRIPTION PRODUCT DEVELOPMENT For personal use only Traditional development Acrux’s generic development portfolio Market size A new drug may have a Attractive market and licensee terms significant market • Market value of drugs in pipeline >US$1.4bn opportunity, ho
Slide 7: Acrux Is Making Excellent Progress Across Its Generic Topical Portfolio
ACRUX IS MAKING EXCELLENT PROGRESS ACROSS ITS GENERIC TOPICAL PORTFOLIO For personal use only Overview of Acrux’s current generic topical portfolio of 13 assets In FY19, Acrux intends to: Formulation Process Bioequiv. / Regulatory Approved / Development Development clinical2 Submission Launched ✓ Su
Slide 8: Acrux Pipeline Represents a Large Market with Relatively Low Competition
ACRUX PIPELINE REPRESENTS A LARGE MARKET WITH RELATIVELY LOW COMPETITION For personal use only Acrux topical generic pipeline addressable market value 1 ($USm) # of commercialised generic Acrux’s portfolio (13 products) is targeting a significant (ANDA) competitors addressable market on the market 1
Slide 9: First Generic Topical Product to Reach FDA Review Targeting ~US$280m Market
FIRST GENERIC TOPICAL PRODUCT TO REACH ‘FDA REVIEW’ IS TARGETING A ~US$280m MARKET For personal use only Jublia® (efinaconazole) Topical Solution, 10% is a prescription antifungal What is Jublia®? medicine used to treat fungal infections of the toenails (Onychomycosis) FEB-16: JUN-18: NOTE: Acrux ha
Slide 10: Illustrative View of Commercialisation Path for Generic Version of Jublia
ILLUSTRATIVE VIEW OF COMMERCIALISATION PATH FOR ACRUX’S GENERIC VERSION OF JUBLIA® For personal use only Submit dossier to Secure licensing Launch product FDA for filing agreement Generate ongoing revenue stream [TIMING TBD] [COMPLETE] [ONGOING] ✓ Acrux submitted dossier ✓ Acrux will seek to ✓ Acrux
Slide 11: Rapid Market Share Gains Typically Achieved by New Generic Products
RAPID MARKET SHARE GAINS TYPICALLY ACHIEVED BY NEW GENERIC PRODUCTS For personal use only Generics with exclusivity reached a peak market share Acrux’s generic version of of >50%1 on average during the exclusivity period Jublia® is expected to be granted First-to-File status 55% and benefit from exc
Slide 12: Acrux Is Operating in an Attractive US$18bn Market
ACRUX IS OPERATING IN AN ATTRACTIVE US$18bn MARKET For personal use only >US$400bn1 ~US$18bn2 Topical generics represent an attractive and significant market opportunity 12% Other 4% Topical ✓ US$18bn market opportunity 47% Generic ✓ Currently, generics make up only 47% of the topical market, this i
Slide 13: Global Generic Companies Place High Value on Generic Products and Portfolios
GLOBAL GENERIC COMPANIES PLACE HIGH VALUE ON GENERIC PRODUCTS AND GENERIC PORTFOLIOS For personal use only Assumed Enterprise value $40.5bn $16.8bn $8.1bn $7.2bn $880m $42m EBITDA 15x 20x 19x 13x 26x Not released multiple1 Deal date Aug 2016 Sep 2015 Sep 2015 Aug 2016 Jul 2015 May 2015 Target Acquir
Slide 14: Experienced Management Team with Proven History of Meeting Operational Milestones
EXPERIENCED MANAGEMENT TEAM WITH A PROVEN HISTORY OF MEETING OPERATIONAL MILESTONES For personal use only Management team World class topical R&D team Michael Kotsanis BSc, MBus “I am extremely proud to lead an expert CEO & Managing Director topical drug development team. Our in- Experienced leader
Slide 15: Strategic Direction Led by a Board with Highly Relevant Expertise
STRATEGIC DIRECTION LED BY A BOARD WITH HIGHLY RELEVANT EXPERTISE For personal use only Michael Kotsanis Ross Dobinson CEO & Managing Director Non-Executive • Experienced leader in the pharmaceuticals industry with Chairman demonstrated success commercialising generic products Capital markets expert
Slide 16: Corporate Overview
CORPORATE OVERVIEW For personal use only Trading Information Share price performance (last 12 months) Share Price (A$) Volume (m) Share price (as at 14 September 2018) A$0.235 0.3 8 Shares outstanding1 166.5m 7 Market capitalisation A$39.1m 0.25 6 Cash (as at 30 June 2018) A$28.5m 0.2 Implied enterp
Slide 17: Multiple Upcoming Value Catalysts
MULTIPLE UPCOMING VALUE CATALYSTS Upcoming news flow For personal use only Acrux will keep the market Acrux objectives updated as it continues development of its current FY19 pipeline of 13 generic topical drugs. Potential news flow includes: 2 additional 6 technical Additional new ✓ Dossier accepta
Slide 18: Thank You
For personal use only THANK YOU Investor relations Michael Kotsanis Anthony England Acrux Limited Vesparum Capital CEO & Managing Director Director P: + 61 3 8379 0100 P: + 61 3 8582 4800 E: michael.kotsanis@acrux.com.au E: Acrux@vesparum.com Visit our website: http://www.acrux.com.au/ Follow us on